Synlett 2015; 26(02): 167-172
DOI: 10.1055/s-0034-1379613
letter
© Georg Thieme Verlag Stuttgart · New York

Synthesis and Ring Transformation of Oxygen and Nitrogen Spiro Bisheterocycles

Oualid Talhi*
a   QOPNA, Department of Chemistry, University of Aveiro, 3810–193 Aveiro, Portugal   eMail: artur.silva@ua.pt   eMail: oualid.talhi@ua.pt
c   Centre de Recherche Scientifique et Technique en Analyses Physico-Chimiques CRAPC, BP384, Bou-Ismail, 42004, Tipaza, Algeria
,
Diana C. G. A. Pinto
a   QOPNA, Department of Chemistry, University of Aveiro, 3810–193 Aveiro, Portugal   eMail: artur.silva@ua.pt   eMail: oualid.talhi@ua.pt
,
Filipe A. Almeida Paz
b   CICECO Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
,
Maamar Hamdi
d   Département de Chimie, USTHB, BP32 El Alia, Bab Ezzouar, 16111 Alger, Algeria
,
Artur M. S. Silva*
a   QOPNA, Department of Chemistry, University of Aveiro, 3810–193 Aveiro, Portugal   eMail: artur.silva@ua.pt   eMail: oualid.talhi@ua.pt
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 28. September 2014

Accepted: 02. November 2014

Publikationsdatum:
09. Dezember 2014 (online)


Abstract

A facile and rapid access to bridgehead oxygen- and nitrogen-containing spiro bisheterocycles is reported. It involves a one-pot spiro-to-spiro ring transformation of the key spiro[chromanone-hydantoin] compounds into new substituted spiro [hydantoin-diazole], spiro [hydantoin-isoxazole], spiro [hydantoin-diazepine], spiro [hydantoin-oxazepine], and spiro [hydantoin-benzodiazepine] upon reaction with appropriate bisnucleophilic agents. The hydantoin cycle is preserved during these chemical reactions affording the spiro bisheterocycles in optimal yields (42–71%). This relevant spiro-to-spiro ring transformation was confirmed by NMR and single-crystal X-ray diffraction studies.

Supporting Information

 
  • References and Notes

    • 1a Rompaey KV, Ballet S, Tömböly C, De Wachter R, Vanommeslaeghe K, Biesemans M, Willem R, Tourwé D. Eur. J. Org. Chem. 2006; 13: 2899
    • 1b Somu RV, Johnson RL. J. Org. Chem. 2005; 70: 5954
    • 1c Genin MJ, Mishra RK, Johnson RL. J. Med. Chem. 1993; 36: 3481
  • 2 Zhao Y, Bernard D, Wang S. BioDiscovery 2013; 8: 1
  • 3 Cottin T, Pyrkotis C, Stathakis CI, Mavridis I, Katsoulis IA, Anastasopoulou P, Kythreoti G, Zografos AL, Nahmias VR, Papakyriakou A, Vourloumis D. ChemBioChem 2011; 12: 71
  • 4 Bunyapaiboonsri T, Yoiprommarat S, Intereya K, Rachtawee P, Hywel-Jones NL, Isaka M. J. Nat. Prod. 2009; 72: 756
  • 5 Fisher A, Bar-Ner N, Nachum V. US 20110281903, 2011
  • 6 Fourtillan J.-B. PCT/FR 1995000443, 1995
  • 7 Hamblett C. US 12227417, 2012
  • 8 Berkovic G, Krongauz V, Weiss V. Chem. Rev. 2000; 100: 1741
  • 9 Svêtlík J, Kettmann V. Tetrahedron Lett. 2011; 52: 1062
  • 10 Prajapati D, Bhuyan D, Gohain M, Hu W. Mol. Diversity 2011; 15: 257
  • 11 Singh SN, Regati S, Paul AK, Layek M, Jayaprakash S, Reddy KV, Deora GS, Mukherjee S, Pal M. Tetrahedron Lett. 2013; 54: 5448
  • 12 Pal S, Khan MdN, Karamthulla S, Abbas SkJ, Choudhury LH. Tetrahedron Lett. 2013; 54: 5434
  • 13 Wang Z.-D, Dong N, Wang F, Li X, Cheng J.-P. Tetrahedron Lett. 2013; 54: 5473
  • 14 Pesquet A, Othman M. Tetrahedron Lett. 2013; 54: 5227
  • 15 Azizian J, Shaabanzadeh M, Hatamjafari F, Mohammadizadeh MR. ARKIVOC 2006; (xi): 47
  • 16 Kusanur RA, Ghate M, Kulkarni MV. J. Chem. Sci. 2004; 116: 265
  • 17 Talhi O, Fernandes JA, Pinto DC. G. A, Paz FA. A, Silva AM. S. Tetrahedron 2013; 69: 5413
  • 18 Synthesis of (R,S)-1′,3′-Dicyclohexyl-3-(2′′-hydroxyphenyl)-spiro[1-methyl-4,5-dihydro-1H-pyrazole-5,4′-imidazolidine]-2′,5′-dione (2a)C24H32N4O3 (white crystal, molecular weight 424.53 g/mol, 0.65 g, yield 61%, mp 118–120 °C). Compound 1a (1 g, 2.5 mmol) was added to of methylhydrazine (1 mL, 18.8 mmol) in CH2Cl2 (20 mL). The reaction mixture was stirred at r.t. for 1 h. After that, the volume of CH2Cl2 was reduced to ca. 5 mL to be purified in short plug column chromatography using CH2Cl2 as eluent. The purified product 2a was recrystallized from hexane–acetone (5:1) solution by slow evaporation at 6 °C. 1H NMR (300.13 MHz, CDCl3): δ = 1.09–2.25 (m, 20 H, CH2, cyclohexyl), 2.88 (s, 3 H, NCH3), 3.13 (tt, J = 12.0, 3.7 Hz, 1 H, H-1′′′b), 3.35 and 3.63 (AB, J = 17.7 Hz, 2 H, H-4), 3.91 (tt, J = 12.4, 3.9 Hz, 1 H, H-1′′′a), 6.89 (ddd, J = 7.4, 5.4, 1.2 Hz, 1 H, H-5′′), 6.98–7.02 (m, 2 H, H-3′′), 7.08 (dd, J = 7.4, 1.7 Hz, 1 H, H-6′′), 7.23–7.29 (m, 1 H, H-4′′), 10.39 (s, 1 H, 2′′-OH) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 24.9, 25.0, 25.71, 25.71, 26.02, 26.03, 29.3, 29.5,30.2 and 30.9 (CH2, cyclohexyl), 34.9 (NCH3), 40.5 (C-4), 51.4 (C-1′′′a), 53.5 (C-1′′′b), 83.7 (C-5/4′), 115.7 (C-1′′), 116.7 (C-3′′), 119.2 (C-5′′), 126.8 (C-6′′), 130.5 (C-4′′), 149.5 (C-3), 153.9 (C-2′), 157.2 (C-2′′), 170.2 (C-5′) ppm. HRMS (ESI+): m/z calcd for [C24H32N4O3 + Na]+: 447.2372; found: 447.2385.
  • 19 Synthesis of (R,S)-1′,3′-Dicyclohexyl-3-(2′′-hydroxyphenyl)-spiro[4,5-dihydroisoxazole-5,4′-imidazolidine]-2′,5′-dione (3a)C23H29N3O4 (yellowish white solid, molecular weight 411.49 g/mol, 0.43 g, yield 42%, mp 91–92 °C). Compound 1a (1 g, 2.5 mmol) was added to K2CO3 (1 g, 7.5 mmol) in acetone (40 mL). The reaction mixture was stirred at reflux to which hydroxylammonium chloride (1 g, 14.4 mmol) was gradually added over a period of 10 min. After 15 h, K2CO3 was filtered off, and the solution was reduced to ca. 5 mL to which hexane (25 mL) was added. The purified product 3a was directly recrystallized from this hexane–acetone (5:1) solution by slow evaporation at 6 °C without any further purification steps. 1H NMR (300.13 MHz, DMSO-d 6): δ = 1.00–1.99 (m, 20 H, CH2, cyclohexyl), 3.37 (tt, J = 12.1, 3.6 Hz, 1 H, H-1′′′b), 3.67 (tt, J = 12.1, 3.6 Hz, 1 H, H-1′′′a), 3.68 and 3.71 (AB, J = 15.4 Hz, 2 H, H-4), 7.40 (ddd, J = 7.9, 5.8, 2.1 Hz, 1 H, H-5′′), 7.62–7.66 (m, 2 H, H-3′′, H-4′′), 7.87–7.91 (m, 1 H, H-6′′) ppm. 13C NMR (75.47 MHz, DMSO-d 6): δ = 25.8, 26.1, 26.3, 26.4, 26.80, 26.84, 29.3, 30.2, 31.4 and 31.8 (CH2, cyclohexyl), 31.0 (C-4), 51.3 (C-1′′′a), 53.0 (C-1′′′b), 86.1 (C-5/4′), 110.2 (C-3′′), 122.5 (C-1′′), 123.1 (C-6′′), 124.2 (C-5′′), 131.0 (C-4′′), 153.8 (C-3), 154.5 (C-2′), 163.5 (C-2′′), 172.4 (C-5′) ppm. HRMS (ESI+): m/z calcd for [C23H29N3O4 + Na]+: 434.2056; found: 434.2075.
  • 20 Synthesis of (R,S)-1′,3′-Dicyclohexyl-7-(2′′-hydroxyphenyl)-spiro[(E)-3,4,5,6-tetrahydro-2H-1,4-diazepine-5,4′-imidazolidine]-2′,5′-dione (4a) and (R,S)-1′,3′-Diisopropyl-7-(2′′-hydroxyphenyl)-spiro[(E)-3,4,5,6-tetrahydro-2H-1,4-diazepine-5,4′-imidazolidine]-2′,5′-dione (4b)Compound 1a (1 g, 2.5 mmol) or 1b, (0.8 g, 2.5 mmol) was added to ethylenediamine (1 mL, 15 mmol) in CH2Cl2 (20 mL). The reaction mixture was stirred at r.t. for 4 h. After that, the volume of CH2Cl2 was reduced to ca. 5 mL to be purified in short plug column chromatography using CH2Cl2 as eluent. The purified products 4a or 4b were recrystallized from hexane–CH2Cl2 (5:1) solution by slow evaporation at 6 °C. In the case of compound 4b synthesis, the byproduct 7b was isolated by column chromatography and precipitated in hexane.Compound 4a: C25H34N4O3 (pale yellow solid, molecular weight 438.56 g/mol, 0.49 g, yield 45%, mp 178–179 °C). 1H NMR (300.13 MHz, CDCl3): δ = 1.06–2.34 (m, 20 H, CH2, cyclohexyl), 3.00–3.07 and 3.61–3.69 (2 m, 2 H, CH2, H-3), 3.25 and 3.34 (AB, J = 14.6, 2 H, H-6), 3.24 and 3.80 (2 tt, J = 12.3, 3.8 Hz, 2 H, H-1′′′a, H-1′′′b), 3.88 (ddd, J = 14.1, 9.1, 2.3 Hz, 1 H, H-2), 4.17 (ddd, J = 14.1, 6.6, 1.8 Hz, 1 H, H-2), 6.73 (ddd, J = 8.2, 7.2, 1.2 Hz, 1 H, H-5′′), 6.93–6.98 (m, 1 H, H-3′′), 7.22 (dd, J = 8.1, 1.5 Hz, 1 H, H-6′′), 7.27–7.31 (m, 1 H, H-4′′), 15.79 (s, 1 H, 2′′-OH) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 24.81, 24.88, 25.68, 25.71, 26.03, 26.1, 29.0, 29.4, 30.9 and 31.3 (CH2, cyclohexyl), 35.9 (C-6), 41.2 (C-3), 49.9 (C-2), 50.9 and 52.5 (C-1′′′a and C-1′′′b), 72.1 (C-5/4′), 117.1 (C-5′′), 118.93 and 118.98 (C-3′′, C-1′′), 127.2 (C-6′′), 132.8 (C-4′′), 153.3 (C-2′), 163.5 (C-2′′), 171.5 (C-7), 171.9 (C-5′) ppm. HRMS (ESI+): m/z calcd for [C25H34N4O3 + H]+: 439.2709; found: 439.2742.Compound 4b: C19H26N4O3 (bright yellow crystal, molecular weight 358.43 g/mol, 0.60 g, yield 67%, mp 193–195 °C). 1H NMR (300.13 MHz, CDCl3): δ = 1.32, 134 and 1.47 (3d, J = 6.9 Hz, 3 × 3 H, CH3, isopropyl), 1.43 (d, J = 6.8 Hz, 3 H, CH3, isopropyl), 1.86–1.97 (m, 1 H, NH), 3.00–3.07 and 3.62–3.69 (2 m, 2 H, H-3), 3.27 and 3.32 (AB, J = 15.0 Hz, 2 H, H-6), 3.82–3.88 and 4.13–4.19 (2 m, 2 H, H-2), 3.70–3.81 and 4.19–4.28 (2 m, 2 H, H-1′′′a, H-1′′′b), 6.71–6.75 (m, 1 H, H-5′′), 6.95 (dd, J = 8.3, 1.1 Hz, 1 H, H-3′′), 7.22 (dd, J = 8.1, 1.4 Hz, 1 H, H-6′′), 7.26–7.30 (m, 1 H, H-4′′), 15.75 (s, 1 H, 2′′-OH) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 19.5, 19.8, 21.2 and 21.7 (CH3, isopropyl), 36.0 (C-6), 41.5 (C-3), 43.4 and 44.5 (C-1′′′a and C-1′′′b), 50.2 (C-2), 72.2 (C-5/4′), 117.2 (C-5′′), 119.0 (C-3′′), 119.1 (C-1′′), 127.3 (C-6′′), 132.9 (C-4′′), 153.2 (C-2′), 163.5 (C-2′′), 171.5 (C-7), 172.0 (C-5′) ppm. HRMS (ESI+): m/z calcd for [C19H26N4O3 + H]+: 359.2083; found: 359.2115.(E,Z)-5-[2′-(2′′-Hydroxyphenyl)-2′-oxoethylidene]-1,3-diisopropylimidazolidine-2,4-dione (7b)C17H20N2O4 (yellow solid, molecular weight 316.35 g/mol, 0.06 g, yield 8%, mp 144–145 °C). 1H NMR (300.13 MHz, CDCl3): δ = 1.46 and 1.49 (2d, J = 6.9 Hz, 2 × 6 H, CH3, isopropyl), 4.32–4.55 (m, 2 H, H-1′′′a, H-1′′′b), 6.82 (s, 1 H, H-1′), 6.98–6.99 (m, 1 H, H-5′′), 7.02 (d, J = 8.4 Hz, 1 H, H-3′′), 7.47–7.57 (m, 1 H, H-4′′), 7.84 (d, J = 8.1 Hz, 1 H, H-6′′), 12.27 (s, 1 H, 2′′-OH) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 19.7 and 20.0 (CH3 isopropyl), 44.5 and 50.5 (C-1′′′a and C-1′′′b), 100.5 (C-1′), 118.6 (C-3′′), 119.2 (C-5′′), 120.8 (C-1′′), 130.8 (C-6′′), 137.0 (C-4′′), 137.2 (C-5), 153.9 (C-2), 162.9 (C-2′′), 1623.0 (C-4), 194.8 (C-2′) ppm. HRMS (ESI+): m/z calcd for [C17H20N2O4 + Na]+: 339.1321; found: 339.1315.
  • 21 Synthesis of (R,S)-1′,3′-Dicyclohexyl-5-(2′′-hydroxyphenyl)-spiro[(E)-2,3,6,7-tetrahydro-2H-1,4-oxazepine-7,4′-imidazolidine]-2′,5′-dione (5a)C25H33N3O4 (yellowish white solid, molecular weight 439.54 g/mol, 0.65 g, yield 59%, mp 96–97 °C). Compound 1a (1g, 2.5 mmol) was added to hydroxyethylene amine (or 2-aminoethanol) (1 mL, 16.5 mmol) in CH2Cl2 (20 mL). The reaction mixture was stirred at r.t. for 4 h. The volume of CH2Cl2 was then reduced to ca. 5 mL to be purified in short plug column chromatography using CH2Cl2 as eluent. The purified product 5a was precipitated in hexane. 1H NMR (300.13 MHz, CDCl3): δ = 0.93–2.30 (m, 20 H, CH2, cyclohexyl), 2.57–2.60 (m, 2 H, H-2), 3.11 (tt, J = 12.0, 3.5 Hz, 1 H, H-1′′′a), 3.47 and 3.65 (AB, J = 17.8 Hz, 2 H, H-6), 3.62–3.73 (m, 2 H, H-3), 3.97 (tt, J = 12.0, 3.5 Hz, 1 H, H-1′′′b), 6.86–7.01 (m, 2 H, H-5′′, H-3′′), 7.45–7.53 (m, 1 H, H-4′′), 7.65 (dd, J = 8.1, 1.2 Hz, 1 H, H-6′′), 11.74 (s, 1 H, 2′′-OH) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 25.07, 25.13, 25.81, 25.87, 26.1, 26.2, 29.2, 29.3, 30.2 and 30.5 (CH2, cyclohexyl), 42.4 (C-6), 42.7 (C-2), 51.5 (C-1′′′b), 52.1 (C-1′′′a), 61.5 (C-3), 75.5 (C-7/4′), 118.7 (C-1′′), 118.9 (C-5′′), 119.2 (C-3′′), 129.2 (C-6′′), 137.1 (C-4′′), 155.1 (C-2′), 162.6 (C-2′′), 173.5 (C-5′), 200.5 (C-5) ppm. HRMS (ESI+): m/z calcd for [C25H33N3O4 Na]+: 462.2369; found: 462.2342.
  • 22 Synthesis of (R,S)-1′,3′-Dicyclohexyl-4-(2′′-hydroxyphenyl)-spiro[(E)-2,3-dihydro-1H-benzo[b][1,4]diazepine-2,4′-imidazolidine]-2′,5′-dione (6a) and (R,S)-1′,3′-Diisopropyl-4-(2′′-hydroxyphenyl)-spiro[(E)-2,3-dihydro-1H-benzo[b][1,4]diazepine-2,4′-imidazolidine]-2′,5′-dione (6b)Compound 1a (1 g, 2.5 mmol) or 1b (0.8 g, 2.5 mmol), was added to ortho-phenylenediamine (0.54 g, 5 mmol) in THF (40 mL) in the presence of a catalytic amount of DBU (few drops). The reaction mixture was stirred at reflux overnight. After that, the solution was reduced to ca. 5 mL to be purified in short plug column chromatography using CH2Cl2 as eluent. The purified product 6a or 6b, was recrystallized from a hexane–CH2Cl2 (5:1) solution by slow evaporation at 6 °C.Compound 6a: C29H34N4O3 (pale yellow crystal, molecular weight 486.60 g/mol, 0.86 g, yield 71%, mp 147–149 °C). 1H NMR (300.13 MHz, CDCl3): δ = 0.69–2.29 (m, 20 H, CH2, cyclohexyl), 2.99 and 3.33 (AB, J = 14.0 Hz, 2 H, H-3), 3.06–3.19 and 3.82–3.97 (2 m, 2 H, H-1′′′a, H-1′′′b), 3.77 (s, 1 H, NH), 6.82–6.88 (m, 1 H, H-5′′), 6.89–6.93 (m, 1 H, H-7), 7.04 (d, J = 8.8 Hz, 1 H, H-3′′), 7.14–7.19 (m, 2 H, H-8 and H-9), 7.28–7.41 (m, 3 H, H-4′′, H-6′′, H-6), 14.71 (s, 1 H, 2′′-OH) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 22.6, 24.8, 25.7, 25.8, 25.9, 26.1, 29.2, 29.4, 30.8 and 31.5 (CH2, cyclohexyl), 33.5 (C-3), 51.3 and 51.7 (C-1′′′a and C-1′′′b), 87.4 (C-2/4′), 118.1 (C-5′′), 118.5 (C-3′′), 119.1 (C-1′′), 121.5 (C-7), 123.6 (C-9), 127.6 (C-8), 128.1 (C-6), 128.5 (C-6′′), 133.4 (C-4′′), 135.3 (C-9a), 136.0 (C-5b), 152.7 (C-2′), 162.1 (C-2′′), 167.0 (C-4), 170.5 (C-5′). HRMS (ESI+): m/z calcd for [C29H34N4O3 + Na]+: 509.2529; found: 509.2527.Compound 6a: C23H26N4O3 (bright yellow crystal, molecular weight = 406.47 g/mol, 0.64 g, yield 63%, mp 181–182 °C). 1H NMR (300.13 MHz, CDCl3): δ = 1.33 and 1.47 (2 d, J = 6.7 Hz, 2 × 3 H, CH3, isopropyl), 1.41 and 1.44 (2 d, J = 7.2 Hz, 2 × 3 H, CH3, isopropyl), 3.00 and 3.32 (AB, J = 14.0 Hz, 2 H, H-3), 3.56–3.69 and 4.25–4.39 (2 m, 2 H, H-1′′′a, H-1′′′b), 3.83 (s, 1 H, NH), 6.80–6.88 (m, 1 H, H-5′′), 6.90–6.96 (m, 1 H, H-7), 7.04 (d, J = 8.2 Hz, 1 H, H-3′′), 7.10–7.21 (m, 2 H, H-8 and H-9), 7.24–7.42 (m, 3 H, H-4′′, H-6′′, H-6), 14.74 (s, 1 H, 2′′-OH) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 19.6, 19.7, 22.0 and 21.6 (CH3, isopropyl), 33.5 (C-3), 43.7 and 45.6 (C-1′′′a and C-1′′′b), 87.1 (C-2/4′), 118.1 (C-5′′), 118.6 (C-3′′), 119.2 (C-1′′), 121.6 (C-7), 123.6 (C-9), 127.7 (C-8), 128.3 (C-6), 128.6 (C-6′′), 133.4 (C-4′′), 135.3 (C-9a), 135.8 (C-5b), 152.5 (C-2′), 162.2 (C-2′′), 166.7 (C-4), 170.6 (C-5′). HRMS (ESI+): m/z calcd for [C23H26N4O3 + Na]+: 407.2083; found: 407.2100.
  • 23 Crystal Data for Compound 2a2 × C24H32N4O3 + C3H6O, M = 907.15, monoclinic, space group C2/c, Z = 4, a = 29.894(3) Å, b = 8.2853(8) Å, c = 22.364(2) Å, β = 120.814(4)º, V = 4757.1(8) Å3, μ(Mo Kα) = 0.085 mm–1, D c = 1.267 g cm–3, colorless block, crystal size of 0.26 × 0.20 × 0.18 mm3. Of a total of 68339 reflections collected, 6395 were independent (R int = 0.0615). Final R1 = 0.0438 [I > 2σ(I)] and wR2 = 0.1201 (all data). Data completeness to θ = 25.24°, 99.7%. CCDC 1024617.
  • 24 Crystal Data for Compound 4bC19H26N4O3, M = 358.44, monoclinic, space group P21/c, Z = 4, a = 10.3118(13) Å, b = 10.8672(14) Å, c = 17.551(2) Å, β = 105.671(4)º, V = 1893.7(4) Å3, μ(Mo Kα) = 0.087 mm–1, D c = 1.257 g cm–3, yellow block, crystal size of 0.30 × 0.28 × 0.24 mm3. Of a total of 50806 reflections collected, 5091 were independent (R int = 0.0341). Final R1 = 0.0453 [I > 2σ(I)] and wR2 = 0.1219 (all data). Data completeness to θ = 25.24°, 99.9%. CCDC 1024618.
  • 25 Crystal Data for Compound 6bC23H26N4O3 + CH2Cl2, M = 491.40, monoclinic, space group P21/c, Z = 4, a = 14.4092(9) Å, b = 9.1504(5) Å, c = 18.5751(11) Å, β = 98.7540(19)º, V = 2420.6(2) Å3, μ(Mo Kα) = 0.302 mm–1, D c = 1.348 g cm–3, yellow prism, crystal size of 0.20 × 0.20 × 0.16 mm3. Of a total of 19864 reflections collected, 6504 were independent (R int = 0.0332). Final R1 = 0.0741 [I > 2σ(I)] and wR2 = 0.1817 (all data). Data completeness to θ = 25.24°, 99.8%. CCDC 1024619.